This is the authors' abstract. We don't add key points for this paper.
Digital twins (DTs) are emerging as the central enabler for an Industry 4.0 approach to pharmaceutical freeze-drying, promising real-time insight, closed-loop control and virtual validation of processes that are traditionally conservative, lengthy and material-intensive. This paper consolidates expertise from academia, equipment suppliers and biopharma manufacturers to define a five-level DT maturity model for lyophilization and to map the technologies, methodologies and regulatory concepts needed to progress through those levels. We first analyze the physical, mathematical and computational challenges unique to freezing, primary and secondary drying, and show how first-principles, CFD, coupled and probabilistic models can be combined with advanced PAT (wireless temperature probes, TDLAS, dP-dT mass-flow calculation, RGA, NIR) to create a continuously updated design space that is both equipment- and scale-aware. The ISO 23247 reference architecture is then translated into a lyophilization context to standardize data models and information exchange. Commercial platforms (Siemens xDT, Ansys Twin Builder, IMA Sentinel) are reviewed to illustrate implementation pathways, while emerging technologies-spray freeze-drying, RF/microwave heating and AI-enabled visual inspection-highlight the need for adaptable, hybrid mechanistic-ML twins. Regulatory guidance from FDA, ICH and ASME V&V 40 is synthesized into a risk-based verification and validation strategy that aligns DT credibility with product-quality impact. Finally, a road-map of actionable steps-spanning sensor selection, model calibration, uncertainty quantification, operator training, and data governance-is outlined for organizations to adopt during development, tech transfer, and commercial manufacture. Collectively, these recommendations provide a coherent framework for deploying fit-for-purpose, GMP-compliant DTs that shorten cycle times, enhance robustness and accelerate delivery of high-quality lyophilized products.
No takes yet. Share an insight, caveat, or question.
Kazarin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: